QNRX today
$3.72-$0.12 (-3.12%)close Nov 13, 2026Trend
DailyUptrend (starting)
4 hourBullish
1 hourBearish
15 minBearish
5 minConsolidating
Daily trend turns down below $3.30
Key levels
Resistance$4.25
Resistance$3.88
Support$3.45
Latest news & SEC filings
AnalystCCORF Keeps Buy Rating on Quoin Pharmaceuticals
SEC FilingQuoin Pharmaceuticals Ltd. filed a report on a major company event (Form 8-K)
All QNRX news →About Quoin Pharmaceuticals
Quoin Pharmaceuticals is a specialty pharmaceutical company developing therapies for rare and orphan diseases that lack approved treatments. Its lead candidate, QRX003, is a topical lotion in late-stage development for Netherton Syndrome and Peeling Skin Syndrome, while other programs include QRX008 for scleroderma and topical rapamycin formulations for rare skin conditions. The company runs trials across North America and Europe and has marketing partnerships covering many countries beyond its primary markets in America, Europe, and Asia.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
Quoin Pharmaceuticals Ltd. (QNRX)
What Is the Price Target for QNRX?
SEPT Low Target
$14.00
SEPT Mid Target
$19.00
SEPT High Target
$30.00
Analyst Consensus
$19.00
Is QNRX a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for QNRX.
Start Free Trial →Is QNRX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$19.00
7
Moat Score
NONE
3/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with QNRX?
Insider Signal
BUYING
4 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Carter Denise P. | director officer | Buy | 20,490 | $100K | Aug 31, 2026 |
| Myers Michael | director officer | Buy | 20,490 | $100K | Aug 31, 2026 |
| Lawlor Sally Bridget | officer | Buy | 10,244 | $50K | Aug 31, 2026 |
| Culverwell Anthony James | director | Buy | 6,146 | $30K | Aug 31, 2026 |
| LANGER DENNIS | director | Buy | 34,534 | $178K | Aug 27, 2026 |
| Culverwell Anthony James | director | Buy | 31,352 | $161K | Aug 27, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →QNRX Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for QNRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for QNRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:58:11 | $3.82 | 1,807 | $$7K | SELL |
| 17:06:02 | $3.88 | 2,500 | $$10K | BUY |
| 15:16:24 | $3.76 | 1,500 | $$6K | SELL |
| 19:30:17 | $3.85 | 2,500 | $$10K | BUY |
| 19:21:45 | $3.91 | 1,308 | $$5K | SELL |
5 dark pool trades shown · $$37K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Quoin Pharmaceuticals Ltd. (QNRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →QNRX — frequently asked questions
What is QNRX stock price today?
Quoin Pharmaceuticals Ltd. (QNRX) is at $3.72, down 3.12% (-$0.12) at the Nov 13, 2026 close.
Why is QNRX stock moving today?
Latest QNRX news — Nov 11, 2026: CCORF Keeps Buy Rating on Quoin Pharmaceuticals · Nov 6, 2026: Quoin Pharmaceuticals Ltd. filed a report on a major company event (Form 8-K)
What is the QNRX price target?
The average analyst price target for QNRX is $19.00, ranging from $14 to $30, based on 4 analysts. Latest: Canaccord Genuity initiates on Oct 19, 2026.
What do analysts rate QNRX?
Analyst ratings for QNRX: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did QNRX beat earnings?
QNRX last reported on Nov 5, 2026: EPS -$0.97 vs -$1.52 expected — a beat of 36.0%.
Does QNRX pay a dividend?
QNRX does not currently pay a dividend.
What are QNRX support and resistance levels?
Support: $3.45. Resistance: $3.88, $4.25, $4.62.
What are insiders doing with QNRX?
Insider activity: BUYING, 4 buys and 0 sells in the last 90 days.
What is the latest news on QNRX?
Nov 11, 2026: CCORF Keeps Buy Rating on Quoin Pharmaceuticals · Nov 6, 2026: Quoin Pharmaceuticals Ltd. filed a report on a major company event (Form 8-K)